Sydnexis is decreasing myopic progression in children.

Formulation Matters!
Our patented formulation is designed for comfort and efficacy.
See How

Sydnexis is decreasing myopic progression in children.

See How

A novel, stable, & comfortable topical eyedrop used once daily at bedtime.

See How
The STAR Study Logo

Treating Myopia with the STAR Study

A Phase 3 study to treat the progression of myopia in children.
Learn More

Are you a patient?

Learn more about Myopia & how to treat it.
Click Here

Latest News

Sydnexis welcomes Perry J. Sternberg as Chief Executive Officer
Perry J. Sternberg Joins Sydnexis as Chief Executive Officer Accomplished Industry Leader Brings Extensive Commercialization and Ophthalmic Expertise
Read More
July 16, 2024
Sydnexis Welcomes Erin Horn as Vice President, Head of Market Access
Sydnexis Welcomes Erin Horn as Vice President, Head of Market Access
Read More
January 19, 2024
Previous News
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form. Please try again.
About

Management

Pipeline

Myopia In The News
Why Myopia?
‍
Press Releases

Privacy Policy
CONTACT US
‍
445 Marine View Avenue
Suite 200 Del Mar, CA 92014

858-925-6172
info@sydnexis.com
© Sydnexis 2023

By using this website, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts. View our Privacy Policy for more information.

Accept